SEC Company Response from Evolent Health, Inc. (EVH) (CIK 0001628908) (EVH) — Aug 11, 2016
Evolent Health, Inc. (EVH) (CIK 0001628908)
Date: Aug. 11, 2016 · CIK: 0001628908 · Accession: 0000950157-16-002078
AI Filing Summary & Sentiment
File numbers found in text: 333-212709
Referenced dates: August 10, 2016
Letter
Evolent Health, Inc. Registration Statement on Form S-3 Filed July 28, 2016 File No. 333-212709
Dear Ms. Hunter:
We refer to the letter dated August 10, 2016 (the “Comment Letter”) from the U.S. Securities and Exchange Commission (the “Commission”) to Evolent Health, Inc., a Delaware corporation (the “Company”), setting forth the comment of the staff of the Commission (the “Staff”) with respect to the Company’s Registration Statement on Form S-3, File No. 333-212709, filed on July 28, 2016 (the “Registration Statement”). Set forth below in bold font is the comment of the Staff contained in the Comment Letter and immediately below the comment is the response of the Company with respect thereto.
General
1.
We note that you stated in your response letter to our comment that TPG Global, LLC is an affiliate of a broker-dealer. A selling shareholder who is an affiliate of a broker-dealer must be identified in the prospectus as an underwriter unless the prospectus states, if true, that
·
·
the selling shareholder purchased the shares being registered for resale in the ordinary course of business, and
at the time of the purchase, the selling shareholder had no agreements or understandings, directly or indirectly, with any person to distribute the securities.
Please confirm that, when you identify your selling shareholders, you will identify any selling shareholder who is an affiliate of a broker-dealer as an underwriter unless the prospectus states the above two representations with respect to any such shareholder.
In response to the Staff’s comment, the Company confirms that when it identifies selling shareholders, it will identify any selling shareholder who is an affiliate of a broker-dealer as an underwriter or state the above two representations with respect to any such shareholder.
Please contact me at (212) 474-1131 with any questions regarding the above response.
Very truly yours,
/s/ William V. Fogg
Show Raw Text
CORRESP 1 filename1.htm August 11, 2016 Evolent Health, Inc. Registration Statement on Form S-3 Filed July 28, 2016 File No. 333-212709 Dear Ms. Hunter: We refer to the letter dated August 10, 2016 (the “Comment Letter”) from the U.S. Securities and Exchange Commission (the “Commission”) to Evolent Health, Inc., a Delaware corporation (the “Company”), setting forth the comment of the staff of the Commission (the “Staff”) with respect to the Company’s Registration Statement on Form S-3, File No. 333-212709, filed on July 28, 2016 (the “Registration Statement”). Set forth below in bold font is the comment of the Staff contained in the Comment Letter and immediately below the comment is the response of the Company with respect thereto. General 1. We note that you stated in your response letter to our comment that TPG Global, LLC is an affiliate of a broker-dealer. A selling shareholder who is an affiliate of a broker-dealer must be identified in the prospectus as an underwriter unless the prospectus states, if true, that · · the selling shareholder purchased the shares being registered for resale in the ordinary course of business, and at the time of the purchase, the selling shareholder had no agreements or understandings, directly or indirectly, with any person to distribute the securities. Please confirm that, when you identify your selling shareholders, you will identify any selling shareholder who is an affiliate of a broker-dealer as an underwriter unless the prospectus states the above two representations with respect to any such shareholder. In response to the Staff’s comment, the Company confirms that when it identifies selling shareholders, it will identify any selling shareholder who is an affiliate of a broker-dealer as an underwriter or state the above two representations with respect to any such shareholder. Please contact me at (212) 474-1131 with any questions regarding the above response. Very truly yours, /s/ William V. Fogg William V. Fogg Sandra B. Hunter Staff Attorney Office of Real Estate and Commodities U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Copy to: Bryan Hough Staff Attorney U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Jonathan Weinberg General Counsel Evolent Health, Inc. 800 N. Glebe Road, Suite 500 Arlington, Virginia 22203 BY EDGAR; FED EX 2